Lilly to acquire JPM-founded Calytrix Bio for up to $1.5bn
TLDR
- Eli Lilly agreed to buy Calytrix Bio, a company founded in 2025, for up to $1.5bn in cash.12
- The upfront payment, milestone split and closing date were not disclosed, and the lead drug is preclinical.12
- J.P. Morgan Life Sciences Private Capital founded Calytrix; Westlake BioPartners and Avoro Ventures also backed it.13
Eli Lilly has agreed to acquire Calytrix Bio, a privately held company based in Wellesley Hills, Massachusetts, under a definitive agreement announced by Calytrix on 16 November.1 The release says "Calytrix shareholders could receive up to $1.5 billion in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones".1 Reuters reported that Calytrix did not disclose the size of the upfront payment or when the deal is expected to close, and BioPharma Dive described the milestones as "certain unspecified clinical and regulatory milestones".23 The $1.5bn is therefore a ceiling, not a confirmed price. Paul, Weiss, which advised Lilly, restated the same terms; a separate Lilly release was not located.4
Calytrix's lead asset is "an investigational biparatopic antibody for mutant calreticulin (mCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF)", according to the release, and it has not yet entered human trials.12 pharmaphorum says mCALR is found in roughly 25 to 30 per cent of primary myelofibrosis cases and 20 to 30 per cent of ET cases, making it the second most common driver after JAK2 mutations.5 Citi analysts quoted by Fierce Biotech called the fit with Lilly strategic but cautioned that "the program remains preclinical, and the safety bar will be particularly high in indolent ET".6
The release says Calytrix "was founded in 2025 by J.P. Morgan Life Sciences Private Capital", launched with a Series A "co-led by J.P. Morgan Life Sciences Private Capital and Westlake BioPartners", and then raised a Series B "led by Avoro Ventures".1 Reuters and BioPharma Dive name the same three investors, while BioSpace says the Series A was led by J.P. Morgan and omits Westlake's co-lead role, so that detail rests on the release; BioSpace adds that financial details of both rounds were not disclosed.237 The founding month is not given. Dealroom lists a June 2025 launch (about 17 months before the deal), but that is an unconfirmed aggregator entry.8
In April 2026 it agreed to buy Ajax Therapeutics, which has a Type II JAK2 inhibitor in Phase 1, for up to $2.3bn in cash, and described itself as "a founding strategic investor in Ajax".9 Citi's view, as reported by Fierce, is that Calytrix targets the disease-driving clone rather than downstream JAK signalling.6 The rival to beat is Incyte, whose first-in-class mutant-CALR antibody INCA033989 was reported by the company in June to have produced haematologic responses in 87 per cent of ET patients in Phase 1 (company-reported).10 ApexOnco wrote that "Incyte is the most advanced player targeting mutated CALR protein, but it might end up being challenged by Lilly".11 BioPharma Dive counts 15 Lilly company acquisitions this year, worth more than $30bn, while BioSpace counts 14 disclosed deals, so the tally varies by outlet.37
J.P. Morgan Life Sciences Private Capital closed its first biotech venture fund at over $500M in June 2024.12 In December 2024 it took part in Ottimo Pharma's Series A of over $140M.13 Avoro Capital led Ethyreal Bio's Series B in June 2026; that release names a partner as head of Avoro Ventures, so this article treats the two names as one investor group.14 Westlake lists Calytrix on its portfolio page.15
Why it matters: a venture-built antibody company founded in 2025 reached an acquisition worth up to $1.5bn before entering human trials, but without a disclosed upfront payment the cash actually paid is unknown, and Incyte is further ahead in mutant CALR.1211
Sources
- Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis (PR Newswire (Calytrix Bio))
- Lilly to buy Calytrix for up to $1.5 billion in rare blood cancer bet (Reuters (via Investing.com))
- Lilly adds to buyout streak with $1.5B purchase of startup Calytrix (BioPharma Dive)
- Eli Lilly to Acquire Calytrix Bio in up to $1.5 Billion Deal (Paul, Weiss)
- Lilly strikes again, buying Calytrix in $1.5bn deal (pharmaphorum)
- Lilly secures another myelofibrosis option via $1.5B deal for JPM-founded Calytrix (Fierce Biotech)
- Lilly's early-stage M&A quest finds $1.5B deal for Calytrix's blood cancer work (BioSpace)
- Calytrix Bio company information, funding & investors (Dealroom.co)
- Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera (Eli Lilly and Company)
- Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia (Incyte)
- Lilly plays catch-up in CALR (ApexOnco)
- J.P. Morgan Life Sciences Private Capital Closes Inaugural Biotechnology Venture Capital Fund with over $500 million in Commitments (J.P. Morgan Asset Management)
- Ottimo Pharma Raises over $140 Million in Series A Financing (Ottimo Pharma)
- Ethyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves' Disease (Avoro Capital Advisors)
- Our Portfolio | Startup Biotech Companies (Westlake BioPartners)